-
Mashup Score: 0Jim Burns reunites with Genzyme colleague at Ensoma; Lilly exec to retire after 27 years - 2 day(s) ago
Jim Burns was looking for his next post after his latest venture in biotech, a gene therapy startup known as Locanabio, shut down
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0
GSK and the UK government have pledged £130 million ($165 million) to tackle antimicrobial resistance (AMR) at home and abroad by improving access to existing medicines and diagnostic tools. GSK said it is the first founding partner of the Fleming Initiative with its investment of £45 million ($57 million). The
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
-
Mashup Score: 0The Endpoints Slack interview: Siddhartha Mukherjee on the doctor-writer worldview, AI, and the future of cancer - 5 day(s) ago
Siddhartha Mukherjee is something of a biotech Renaissance man. First and foremost, he sees himself as an oncologist. But that core interest has led him in many directions, including running a research lab at Columbia University, co-founding a growing list of biotech startups, and writing books on science and medicine,
Source: endpts.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 25Trailblazers, iconoclasts and breakthrough artists are coming to the Endpoints biotech summit — please join us - 5 day(s) ago
When Aviv Regev closed out one long chapter of her life at the Broad and stepped into a new job as head of research and early development at Genentech four years ago, she set out to build a whole new approach to drug discovery on top of the broad base
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 22
More details have started to emerge on how exactly Bayer is executing its broader company restructuring. The German conglomerate disclosed that 1,500 full-time employees had been laid off across pharmaceuticals, crop science and consumer health at the end of the first quarter. The company previously described plans for staff cuts
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 20
Shionogi’s once-daily Covid-19 antiviral ensitrelvir missed the primary endpoint in a Phase 3 study, two months after scoring full approval in Japan. In the NIH-partnered SCORPIO-HR study, ensitrelvir didn’t show a statistically significant reduction in “time to sustained resolution,” or patients being completely clear of 15 different symptoms for at
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 2France draws €2B+ research, manufacturing investment from Sanofi, Pfizer, AstraZeneca, GSK - 6 day(s) ago
Sanofi, Pfizer and AstraZeneca separately pledged to increase their footprint in France, with investments adding up to almost €2 billion. The big pharma announcements are a part of a much larger €15 billion investment from various companies in different industries, according to Reuters, as the foreign direct investment summit dubbed
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 12Sanofi takes on Novavax's Covid vaccine for $500M, eyeing commercialization, flu combination - 9 day(s) ago
Sanofi is handing Novavax $500 million upfront to bring the biotech’s Covid-19 vaccine into the fold, with dual goals of co-commercializing the current vaccine and developing combo vaccines that can tackle both Covid and flu. The deal also carries $700 million in development, regulatory and launch milestones, meaning Novavax can
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 29Takeda to shut down San Diego research center - 10 day(s) ago
Takeda is shuttering its San Diego research site, the company confirmed to Endpoints News. The company told employees on Thursday that it will close the site as part of a decision “to focus more of our resources on our promising late-stage pipeline and to ensure we are best positioned to
Source: endpts.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 3
California biotech Bluejay Therapeutics has secured a megaround to continue developing its treatment candidates for chronic hepatitis D and B. The $182 million Series C, disclosed Thursday morning, will bankroll testing of seven programs, including former Novartis and Exicure assets. The biotech’s lead hepatitis asset, BJT-778, derives from Novartis and
Source: endpts.comCategories: General Medicine News, Infectious DiseaseTweet
Alex Hoffman, Kathy Wong and Kyle LaHucik are out with their weekly edition of Peer Review; the best look at industry moves the industry has. If you're interested in biopharma people (and who isn't?) it is by itself a great reason to subscribe. https://t.co/5RiyIUoxVD